Dr. Qiwei W. Gai, MD | Westminster, MD ...

Dr. Qiwei W. Gai

Claim this profile

William E Kahlert Regional Cancer Center/Sinai Hospital

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
17 drugs studied

Area of expertise

1Lung Cancer
Qiwei W. Gai has run 6 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage I
2Non-Small Cell Lung Cancer
Qiwei W. Gai has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage IV

Affiliated Hospitals

Image of trial facility.
William E Kahlert Regional Cancer Center/Sinai Hospital
Image of trial facility.
Sinai Hospital Of Baltimore

Clinical Trials Qiwei W. Gai is currently running

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Qiwei W. Gai

Clinical Trial Related2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Qiwei W. Gai has experience with
  • Pembrolizumab
  • Biospecimen Collection
  • Carboplatin
  • Paclitaxel
  • Questionnaire Administration
  • Crizotinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Qiwei W. Gai specialize in?
Is Qiwei W. Gai currently recruiting for clinical trials?
Are there any treatments that Qiwei W. Gai has studied deeply?
What is the best way to schedule an appointment with Qiwei W. Gai?
What is the office address of Qiwei W. Gai?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security